Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Burning Rock Biotech (BNR) Inventory (2020 - 2025)

Historic Inventory for Burning Rock Biotech (BNR) over the last 6 years, with Q3 2025 value amounting to $7.7 million.

  • Burning Rock Biotech's Inventory fell 1919.1% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 1919.1%. This contributed to the annual value of $8.6 million for FY2024, which is 1173.75% down from last year.
  • As of Q3 2025, Burning Rock Biotech's Inventory stood at $7.7 million, which was down 1919.1% from $8.1 million recorded in Q2 2025.
  • Burning Rock Biotech's Inventory's 5-year high stood at $21.1 million during Q3 2022, with a 5-year trough of $7.7 million in Q3 2025.
  • In the last 5 years, Burning Rock Biotech's Inventory had a median value of $12.9 million in 2023 and averaged $13.5 million.
  • Per our database at Business Quant, Burning Rock Biotech's Inventory soared by 8586.41% in 2021 and then plummeted by 4855.25% in 2023.
  • Burning Rock Biotech's Inventory (Quarter) stood at $18.0 million in 2021, then grew by 5.15% to $18.9 million in 2022, then plummeted by 48.55% to $9.7 million in 2023, then fell by 11.74% to $8.6 million in 2024, then dropped by 10.83% to $7.7 million in 2025.
  • Its Inventory stands at $7.7 million for Q3 2025, versus $8.1 million for Q2 2025 and $9.0 million for Q1 2025.